Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Prospective study of patient-reported depression, and cognitive and functional impairment, and impact on survival and induction mortality in fit adults age ≥60 years receiving intensive chemotherapy (IC) for Acute Myeloid Leukemia (AML): Prospective geriatric assessment (GA) report from ECOG-ACRIN (EA) E2906 randomized study

Blood (2025) 146 (Supplement 1): 882.

https://doi.org/10.1182/blood-2025-882

Published: 2025

Journal Articles

Age-ing study: A prospective evaluation of geriatric, patient-reported and frailty assessments to predict outcomes in older adults with acute myeloid leukemia

Catherine Lai, Thomas Greenwood, E. Paul Wileyto, Nisha Singh, Ashlena Livingston, Amanda Lopez, Selina Luger, Alexander Perl, Ximena Jordan Bruno, Elizabeth Hexner, Shannon McCurdy, Saar Gill, Gary Okano, Ali McBride, Carmelo Alonso, Keith Pratz

Blood (2025) 146 (Supplement 1): 2843.

https://doi.org/10.1182/blood-2025-2843

Published: 2025

Journal Articles

Molecular mutations may influence cytokine expression and critical illness subphenotyping in septic patients with Acute Myeloid Leukemia

Lukas Ronner, Sarah Skuli, Kaitlyn Housel, Mika Esperanza, Matthew Erlich, Todd Miano, Caroline Ittner, Michael Shashaty, John Reilly, Nuala Meyer, Catherine Lai

Blood (2025) 146 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2025-3376

Published: 2025

Journal Articles

Detection of Acute Myeloid Leukemia and related hematologic malignancies by machine learning using complete blood counts

Daphne Campbell, Evani Patel, Regina Padmanabhan, Abigail Doucette, Moulay Larbi Alaoui, Adel Elomri, Catherine Lai

Blood (2025) 146 (Supplement 1): 7865.

https://doi.org/10.1182/blood-2025-7865

Published: 2025

Journal Articles

Assessment of real-world treatment patterns and outcomes of olutasidenib in patients with mutated isocitrate dehydrogenase 1 Acute Myeloid Leukemia previously treated with venetoclax using electronic health record data

Catherine Lai, Pinkal Desai, Yasmin Abaza, Jorge Cortes, Thomas Leahy, Timothy Werwath, Amber Thomassen, Aaron Sheppard

Blood (2025) 146 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2025-4616

Published: 2025

Journal Articles

Inflammatory and metabolic gene signatures predict overall survival and response to venetoclax-based therapy in TP53 mutant AML

Sarah Skuli, Jayakumar Vadakekolathu, Elena Fenu, Kate Bennett, Jem Palma, Jaryse Harris, Olivia Leung, Eesha Balar, Olga Pozdnyakova, Adam Bagg, Andrew Matthews, Martin Carroll, Catherine Lai, Sergio Rutella

Blood (2025) 146 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2025-1734

Published: 2025

Journal Articles

IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 812.

https://doi.org/10.1182/blood-2025-812

Published: 2025

Journal Articles

Trials in progress: Phase IB/II of CPX-351 as maintenance therapy in AML patients ineligible for bone marrow transplantation

Catherine Lai, Kimberley Doucette, Susan Mckay, Ashlena Livingston, Jed Osei, Ella Rutanen, Jacqueline Galdos, Kristina Krstanoska, Nicole Swanson, Kerrie Bouker, James McCloskey

Blood (2025) 146 (Supplement 1): 8255.

https://doi.org/10.1182/blood-2025-8255

Published: 2025

Journal Articles

A phase 1 dose escalation and dose optimization study to evaluate the preliminary safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity profile of AUTX703 in participants with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 6952.

https://doi.org/10.1182/blood-2025-6952

Published: 2025

Journal Articles

Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary Acute Myeloid Leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies

Blood (2025) 146 (Supplement 1): 5215.

https://doi.org/10.1182/blood-2025-5215

Published: 2025

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia

Matthew P Connor, Neeharika Prathapa, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine Lai, Alison W Loren, Selina M Luger, Andrew H Matthews, Shannon R McCurdy, Alexander Perl, David L. Porter, Arlene Zeringue, Joseph H. Oved, Timothy S Olson, Keith W Pratz, Daria V Babushok

Blood (2023) 142 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2023-179383

Published: 2023

Journal Articles

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Blood (2023) 142 (Supplement 1): 955.

https://doi.org/10.1182/blood-2023-180185

Published: 2023

Journal Articles

Patient-Reported Outcome Measures Associated with Overall Survival and Acute Care Use in Patients with Newly Diagnosed Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Acute Lymphoblastic Leukemia

Seiichi Villalona, Xin Wang, Peter Gabriel, Abigail Doucette, Shannon R McCurdy, Alexander Perl, Selina M Luger, Noelle V. Frey, Ximena Jordan Bruno, Elizabeth O Hexner, Daria V Babushok, David L. Porter, Alison W Loren, Keith W Pratz, Catherine Lai

Blood (2023) 142 (Supplement 1): 5183.

https://doi.org/10.1182/blood-2023-178247

Published: 2023

Journal Articles

Optimizing the Integration of Genetic Testing in AML Care in Community Practice: Insights from a Quality Improvement Initiative

Catherine Lai, Adam Bagg, Lindsay Gurska, Shelby Sullivan, Jeffrey Carter, Cherilyn Heggen

Blood (2023) 142 (Supplement 1): 7277.

https://doi.org/10.1182/blood-2023-172976

Published: 2023

Journal Articles

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Blood (2023) 142 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2023-186978

Published: 2023

Journal Articles

Investigating Racially Induced Metabolic and Genomic Signatures Mediating Inferior Survival in African Americans with Acute Myelogenous Leukemia

Lacey Scott Williams, Alexis K Williams, Sarah Elizabeth Mudra, Paul Sackstein, Garrett Diltz, Rachel Zemel, Purnima Sravanti Teegavarapu, Martha P. Mims, Kimberley Doucette, Catherine Lai, Gustavo A. Rivero

Blood (2023) 142 (Supplement 1): 4320.

https://doi.org/10.1182/blood-2023-190898

Published: 2023

Journal Articles

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Ashley D Hadjis, Griffin W White, Christopher Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine Lai, Andrew H Matthews, Mary Ellen Martin, Daria V Babushok, Alexander Perl, David L. Porter, Alison W Loren, Keith W Pratz, Selina M Luger, Shannon R McCurdy

Blood (2023) 142 (Supplement 1): 376.

https://doi.org/10.1182/blood-2023-188978

Published: 2023

Journal Articles

Phase 2 Response-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, and Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Blood (2023) 142 (Supplement 1): 854.

https://doi.org/10.1182/blood-2023-177994

Published: 2023

Journal Articles

Real-World Validation of the European Leukemia Network 2022 Risk Stratification in Acute Myelogenous Leukemia

Sarah Elizabeth Mudra, Paul Sackstein, Lacey Scott Williams, Garrett Diltz, Rachel Zemel, Ashwin Kumar, Purnima Sravanti Teegavarapu, Martha P. Mims, Catherine Lai, Kimberley Doucette, Gustavo A. Rivero

Blood (2023) 142 (Supplement 1): 4297.

https://doi.org/10.1182/blood-2023-189309

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Age-ing study: A prospective evaluation of geriatric, patient-reported and frailty assessments to predict outcomes in older adults with acute myeloid leukemia

Molecular mutations may influence cytokine expression and critical illness subphenotyping in septic patients with Acute Myeloid Leukemia

Detection of Acute Myeloid Leukemia and related hematologic malignancies by machine learning using complete blood counts

Assessment of real-world treatment patterns and outcomes of olutasidenib in patients with mutated isocitrate dehydrogenase 1 Acute Myeloid Leukemia previously treated with venetoclax using electronic health record data

Inflammatory and metabolic gene signatures predict overall survival and response to venetoclax-based therapy in TP53 mutant AML

IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia

Trials in progress: Phase IB/II of CPX-351 as maintenance therapy in AML patients ineligible for bone marrow transplantation

A phase 1 dose escalation and dose optimization study to evaluate the preliminary safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity profile of AUTX703 in participants with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes

Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary Acute Myeloid Leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies

Risk prediction for clonal cytopenia: multicenter real-world evidence

Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Patient-Reported Outcome Measures Associated with Overall Survival and Acute Care Use in Patients with Newly Diagnosed Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Acute Lymphoblastic Leukemia

Optimizing the Integration of Genetic Testing in AML Care in Community Practice: Insights from a Quality Improvement Initiative

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Investigating Racially Induced Metabolic and Genomic Signatures Mediating Inferior Survival in African Americans with Acute Myelogenous Leukemia

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Phase 2 Response-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, and Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Real-World Validation of the European Leukemia Network 2022 Risk Stratification in Acute Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only